PubCo Insight Institutional & Sector Brief: Covering AIM ImmunoTech Inc. (NYSE: AIM) following its 2026-11-12 Form 10-Q. Prepared for PubCo Insight’s verified vault of 22,361 Active Microcap Traders, Prop Desks & Family Offices.
AIM ImmunoTech Inc. (NYSE: $AIM, market capitalization ~$18.0M), led by Thomas Equels, operates across clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization. Primary SEC EDGAR XBRL records reflect capital-markets disclosure via its 2026-09-14 Form 8-K, anchoring investor diligence around balance-sheet runway and commercial execution.
AIM price and volume, last 90 days. Source: Yahoo Finance.
2. Institutional & Family Office Peer Comparison ($PCSA, $CRMD, and $FBIO)
Across our institutional and active small-cap allocator screens benchmarking $AIM against $PCSA, $CRMD, and $FBIO, three factors stand out:
Valuation & Capital Structure Positioning: At a ~$18.0M market capitalization, $AIM trades at a distinct valuation multiple relative to sector comparables ($PCSA, $CRMD, and $FBIO) competing for the same specialist capital.
Institutional & Family Office Overlap: Inside Pulse IR’s 22,361-contact verified investor vault, 165 microcap funds, RIAs, and family offices and 3,120 active small-cap traders track $PCSA, $CRMD, and $FBIO.
Catalyst & Liquidity Alignment: Pairing clean primary-source research citations with direct institutional and family-office introductions helps bridge liquidity gaps ahead of upcoming operating milestones.
PubCo Insight & Pulse IR Institutional Diagnostic
AIM ImmunoTech Inc. ($AIM) AI Search & Capital Desk Snapshot
38 / 100
AI Diligence Visibility
Before family offices, microcap funds, or active sector traders commit capital to $AIM, most run a rapid screen across ChatGPT, Perplexity Finance, and brokerage terminals. Here is how those surfaces currently render AIM ImmunoTech Inc. across clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization:
Diligence Surface
Score
Current Finding
ChatGPT & OpenAI Search
35/100
Surfaces older baseline summaries and misses recent $AIM operating and balance-sheet updates.
Perplexity Finance & Citations
42/100
Relies on generic quote-scraper snippets instead of primary-source peer comparison context for $AIM.
Institutional Peer Screeners
37/100
$AIM is omitted from standard AI peer screens covering clinical-stage pipeline execution, regulatory milestones, and specialty biopharma commercialization.
For AIM ImmunoTech Inc. Management (Capital Introductions + Full-Stack IR): Pulse IR pairs active trader and AI search visibility with direct introductions to our vetted network of 450+ family offices, RIAs, and microcap financing partners (including 165 institutional desks tracking your peer group, on a flat monthly retainer with zero finder fees). To schedule a 10-minute review with CEO Brad Listermann, visit pulseir.co or call 424-250-0042.
Compiled by the PubCo Insight Editorial & Institutional Desk from primary SEC EDGAR disclosures and market data. Published for informational and research purposes only, not investment advice or a buy/sell recommendation.